Parallel Bio's $21M in Series A will drive aim to cut $2B and 9 years from drug development
Cambridge-based biotechnology company Parallel Bio has closed a $21 million Series A funding round led by AIX Ventures.| Drug Discovery and Development
Cambridge-based biotechnology company Parallel Bio has closed a $21 million Series A funding round led by AIX Ventures.| Drug Discovery and Development
They are highly effective at suppressing inflammation and the reducing the activity of the body’s immune system, providing rapid relief from associated symptoms.| Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.| Drug Discovery and Development
Capturing complete, consistent, and contextualized data is vital in AI/ML, especially within the biopharma industry.| Drug Discovery and Development
